Seattle Genetics Hoping Its Adcetris Trials Can Do Double Duty
This article was originally published in The Pink Sheet Daily
Executive Summary
Story outside: Trials in other indications can suffice as confirmatory trials for accelerated approval in the relapsed/refractory settings, FDA says during advisory committee review
You may also be interested in...
Seattle Genetics Will Test Oncology Pricing Acceptance With Adcetris
Now that Seattle Genetics Inc. is making the transition into a commercial drug company with the FDA approval of its oncologic Adcetris, its success will depend on how effectively it can convince payers, patients and physicians that Adcetris is worth its premium price and how well it can extend the drug’s reach to larger patient markets.
Seattle Genetics Will Test Oncology Pricing Acceptance With Adcetris
Now that Seattle Genetics Inc. is making the transition into a commercial drug company with the FDA approval of its oncologic Adcetris, its success will depend on how effectively it can convince payers, patients and physicians that Adcetris is worth its premium price and how well it can extend the drug’s reach to larger patient markets.
Oncology Price Scale Tips Higher: Seattle Genetics Adcetris To Cost Over $100K
Amid record-topping oncology drug prices, yet another high-priced therapy will hit the market, following accelerated approval from FDA.